RESEARCH TRIANGLE PARK, NC – Dec., 13, 2012 – Quintiles today announced that its flagship central laboratory in the U.S. received accreditation from the College of American Pathologists (CAP) Biorepository Accreditation Program. The first of its kind, this accreditation was developed to ensure biorepositories are following best practices for collection and storage of biospecimens.

“We sought this CAP accreditation to underscore Quintiles’ consistent verification of biospecimen quality that we believe will fuel the next generation of personalized therapies and improve patient health worldwide,” said Thomas Wollman, Senior Vice President, Quintiles Global Laboratories. “This accreditation is a reflection of Quintiles’ unwavering commitment to quality in its labs through standard and uniform operating procedures for data and specimen collection, processing and storage.”

"Our goal with the Biorepository Accreditation Program is to improve and standardize quality and consistency in all facets of the acquisition and processing of biospecimens while ensuring the quality and integrity of human specimens and genetic material," said Richard Gomez, MD, FCAP, Chair, CAP’s Council on Accreditation. "The CAP, as it did more than 50 years ago with laboratory accreditation, is breaking new ground with our program devoted to biorepositories accreditation.”

The CAP Biorepository Accreditation Program is a three-year, peer-based accreditation program developed in 2011 to drive the adoption of standards through consistent application of best practices and evidence-based standards. The program is designed to strengthen the quality of patient care by ensuring consistent, verifiable quality of biospecimens and biorepositories that are lacking in the current environment.

As the CAP Biorepository Accreditation Program continues to expand to other countries, Quintiles will pursue accreditation opportunities within its global laboratory network.

About Quintiles

Quintiles is the world’s leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.

Contact:

Phil Bridges, Media Relations (phil.bridges@quintiles.com)
+ 1.919.998.1653 (office)
+1.919.457.6347 (mobile)

Greg Connors, Investor Relations (invest@quintiles.com)
+1.919.998.2000